Motilent specialises in the assessment of digestive diseases using medical image analysis. Our main focus areas include Crohn’s Disease, Irritable Bowel Syndrome (IBS) and Gastroparesis although we support a range of projects across the digestive health.
Understanding gastrointestinal disease
Motilent is a technology company focused on delivering innovative services for the quantitative investigation of the gut.
Motilent’s mission is to change the way we see the gut. We have spent the last 5 years developing new imaging technology that is helping researchers and clinicians understand how the digestive tract works.
Motilent works closely with the research community, providing a range of products, services and expertise to further our understanding of gastrointestinal function.
Stuart A Taylor, Consultant Radiologist and Professor of Medical Imaging, UCL
Dynamic ‘cine’ MRI offers a new and potentially powerful perspective on gastrointestinal function, especially in conditions like Crohn’s where hypo-motility is related to disease activity. Objective assessment of this data with GIQuant could represent an important advance in how we quantify this in the clinic
Who we work with
UK hospitals to harness the power of AI gut-imaging to aid treatment of Crohn’s Disease18th May 2022
UK hospitals to harness the power of AI gut-imaging to aid treatment of Crohn’s Disease £1.2M National Institute for Health and Care Research (NIHR) funding will see more than 10 UK NHS hospitals (3400 patients) utilising GIQuant to improve analysis and management of Crohn’s Disease Inflammatory Bowel Disease (IBD) costs the NHS £720 million a […]
A round up on COVID-19 and the Digestive System.20th April 2022
When COVID-19 appeared on the scene a lot of strange, interesting, and terrible things happened in the world. Of particular interest to me was how many companies in the MedTech space pivoted their technology to meet some aspect of the pandemic. As one of the most niche companies out there, we at Motilent kept our […]
Are we treating to the right target?24th February 2022
Nothing makes more sense than the ‘treat to target concept’ in IBD. Every patient is different, IBD is complex, keeping a close eye on response is central to the precision medicine paradigm and min-maxing healthcare resource. This is why the recent STARDUST study published in Lancet Gastro may have left a few people disappointed where […]
The Power Of Play11th February 2022
Before I worked at Motilent, I was a teaching assistant at a special needs school. Last week, when LEGO MRI scanners started popping up on social media, it made me think of the children I used to work with. For these children, who often struggle with communication, medical appointments can be very scary. MRI is […]
AI gut-imaging software takes on the US with FDA clearance and national hospital partnership23rd November 2021
Motilent’s clinically-validated AI software has received 510k clearance from the US FDA. New collaboration with AI-powered solutions provider Nuance Communications will allow US healthcare clinics using innovative GIQuant software to accurately measure intestinal motility and treatment response using AI medical image analysis
Alex Menys on The Health-tech Podcast19th July 2020
Motilent’s CEO and Founder, Alex Menys speaks with Dr James Somauroo on The Health-Tech podcast. In the show Alex and James talk about the challenges of getting a product to market in the Med-Tech space as well as the the role of regulations, evidence and relationship building with the clinical community. There’s also a good […]